Uncategorized
Tesofensine: The Triple Reuptake Inhibitor for Weight Loss Research
Tesofensine: The Triple Reuptake Inhibitor for Weight Loss Research
Tesofensine is a novel monoamine reuptake inhibitor that targets serotonin, noradrenaline, and dopamine transporters simultaneously — a “triple reuptake inhibition” mechanism that produced some of the largest weight-loss effects observed in clinical trials. It reached phase 3 development for obesity before development paused, and it remains a prominent compound in weight management research. This guide reviews its mechanism, evidence, applications, dosing, and safety.
1. What Is Tesofensine?
Tesofensine (NS2330) is a small-molecule triple monoamine reuptake inhibitor originally developed for neurodegenerative diseases before its potent weight-loss effects were identified in clinical trials. It enhances satiety and energy expenditure through simultaneous inhibition of serotonin, noradrenaline, and dopamine reuptake. While not a peptide, it is widely researched alongside metabolic peptides.
- Compound type: Small-molecule triple reuptake inhibitor
- Other name: NS2330
- Targets: Serotonin, noradrenaline, dopamine transporters
- Administration: Oral capsule
- Status: Research compound (phase 3 completed, not approved)
2. Mechanism of Action
Tesofensine produces weight loss through central and peripheral effects:
- Triple monoamine reuptake inhibition: Increases synaptic serotonin, noradrenaline, and dopamine
- Appetite suppression: Reduces food intake through satiety pathway activation
- Energy expenditure: Increases thermogenesis and resting metabolic rate
- Additive with GLP-1 mechanisms: Studied alongside incretin peptides for synergistic effects
3. The Research Landscape
| Research area | Reported findings |
|---|---|
| Obesity phase 2/3 trials | Weight loss up to ~10% over 24 weeks in completed trials |
| Energy expenditure | Measured increases in resting metabolic rate in clinical studies |
| Appetite ratings | Reduced hunger and increased fullness reported |
| Safety profile | Blood pressure and heart rate increases — key monitoring parameters |
Tesofensine showed among the highest placebo-adjusted weight losses in the metabolic drug field, with development paused largely on cardiovascular safety considerations.
4. Research Applications
- Weight management research: Obesity protocols targeting food intake and thermogenesis
- Combination research: Studied with GLP-1 peptides and metabolic compounds
- Monoamine research: Triple reuptake inhibition models in metabolic regulation
- Appetite neuroscience: Dopamine and noradrenaline roles in food reward
For related metabolic compounds, see our 5-Amino-1MQ guide and MOTS-c guide.
5. Dosing and Protocol Notes
- Trial doses: 0.25-1 mg/day oral, typically once daily
- Dose-response: Higher doses produced greater weight loss but more cardiovascular effects
- Monitoring: Blood pressure, heart rate, and mood assessments recommended
- Protocol duration: Clinical trials ran 12-24 weeks; research cycles vary
6. Side Effects and Considerations
- Cardiovascular effects: Increased blood pressure and heart rate — most significant concern
- Insomnia and anxiety: Stimulant-class effects on sleep and mood
- Dry mouth and nausea: Common dose-dependent adverse events
- Contraindications: Cardiovascular disease, hypertension, pregnancy, and psychiatric conditions
7. Frequently Asked Questions
Is tesofensine approved? It is not approved; development paused after phase 3 despite strong efficacy signals.
How does it compare with GLP-1 peptides? GLP-1 peptides act on incretin satiety pathways; tesofensine acts centrally on monoamines — different mechanisms with complementary potential in research.
Why is blood pressure monitoring important? Triple monoamine reuptake inhibition raises sympathetic tone, requiring cardiovascular monitoring in protocols.
Related Reading
- 5-Amino-1MQ Metabolic Guide
- MOTS-c Metabolic Peptide Guide
- AOD9604 Fat-Burning Guide
- Semaglutide Research Guide
Shop Related Research Compounds
Browse our research catalog, including Tesofensine, 5-Amino-1MQ, and MOTS-c, all supplied with batch COAs.
Disclaimer: This article is for educational and research purposes only. Tesofensine is a research compound not approved for general human use. Always consult qualified professionals regarding research protocols.
Related Research Guides
Expand your peptide research knowledge with our comprehensive guides:
- Peptides for Anti-Aging: Complete Research Guide 2026
- Peptides for Cognitive Enhancement: Nootropic Research Guide 2026
- Peptides for Metabolic Health: Weight Loss Research Guide 2026
- Peptides for Athletic Performance: Muscle Growth Research Guide 2026
